Topics

Hemispherx Biopharma doses first patient with Ampligen in Phase 1 advanced breast cancer study

12:09 EDT 5 Apr 2019 | Proactive Investors

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Tom Equels tells Proactive Investors the company is excited to begin its Phase 1 studies using Ampligen as a combination therapy with Merck's Keytruda cancer drug at the Roswell Park Comprehensive Cancer Center in New York.

The study will establish the safety of the therapies to treat advanced breast cancer. Equels anticipates safety and efficacy indicators six to nine months after full enrollment of the study.

Original Article: Hemispherx Biopharma doses first patient with Ampligen in Phase 1 advanced breast cancer study

NEXT ARTICLE

More From BioPortfolio on "Hemispherx Biopharma doses first patient with Ampligen in Phase 1 advanced breast cancer study"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...